As Suffolk County's only academic medical center, Stony Brook is committed to training the next generation of physicians. Six to 12 residents a year rotate through the Division of Pediatric Nephrology, not only gaining valuable experience in state-of-the-art medicine, but also continually infusing the program with the latest ideas and approaches.
On the research front, Stony Brook participates in numerous studies, allowing patients who qualify access to the novel therapies and approaches only available in clinical trials. Currently, the department is involved in a multi-center, randomized, double-blind, active-control, dose-escalation clinical trial (ClinicalTrials.gov Identifier: NCT01613118) to evaluate the safety and effectiveness of RE-021, the investigational drug, for primary FSGS treatment. The compound is a first-in-class, orally-active, dual-agent with both angiotensin II (Type I) receptor blocker (ARB) and an endothelin receptor subtype A (ETA) blocker activity. The highly selective, dual antagonist actions of the compound have been demonstrated in in vitro binding assays; similar compounds have been shown to reduce proteinuria in patients with nephrotic syndrome. Division of Pediatric Nephrology at Stony Brook plays an active role in Assessment of Worldwide AKI in Pediatrics, Renal Angina and Epidemiology (AWARE); ClinicalTrials.gov Identifier: NCT01987921, examining whether early kidney injury signs will predict severe subsequent AKI in critically ill children and if the incorporation of urinary biomarkers into the renal angina scoring system will improve the prediction of the severe injury. Stony Brook's Pediatric Nephrology Division plays an active part in the the Midwest Pediatric Nephrology Consortium, collaborating on clinical trials in nephrotic syndrome, hypertension, chronic kidney disease and transplantation. In addition for a number of years now, we are part of The North American Pediatric Renal Trials and Collaborative Studies (NAPTRCS), which is creating a North American database on patients with kidney disease, patients undergoing dialysis, and patients who have received transplants.